<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02917863</url>
  </required_header>
  <id_info>
    <org_study_id>THYR69</org_study_id>
    <secondary_id>2015-001248-12</secondary_id>
    <nct_id>NCT02917863</nct_id>
  </id_info>
  <brief_title>Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism</brief_title>
  <official_title>Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meyer Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meyer Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thyroid disorders, in particular hypothyroidism, are associated with gastrointestinal
      impairment, such as celiac disease. A study reported an increased prevalence of celiac
      disease in a large cohort of children affected by congenital hypothyroidism, underlying the
      relationship between these two conditions. The hypothesis of our study is that the onset of
      celiac disorder may be related to the gut concentration of thyroid hormone (TH) in
      hypothyroidism patients treated with replacement therapy. In fact, TH replacement therapy
      showed a low bioavailability with a consequent high gut concentration. Two different
      pharmaceutical formulations (liquid and solid, per os) are available. The liquid one has a
      better absorption profile and bioavailability than the solid; therefore, it is associated
      with a low TH intestinal concentration. According to our hypothesis, the solid TH formulation
      could increase the microbial diversity in the gut instead of the liquid form, due to the high
      local TH concentration. Based on these findings, the purpose of this study is to evaluate the
      effect of two different pharmaceutical formulations of TH on the gut in terms of modification
      of gut microbiota, inflammatory parameters and gut absorption.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects on gut inflammation parameter (Calprotectin)</measure>
    <time_frame>0-6-12 months</time_frame>
    <description>Calculate the difference in gut inflammation parameter (calprotectin) among the two groups of patients at T6-T0 and T12-T6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects on gut absorption parameters</measure>
    <time_frame>0-6-12 months</time_frame>
    <description>Calculate the difference in gut absorption parameters (Steatocrit) among the two groups of patients at T6-T0 and T12-T6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects on gut inflammation parameter (Osteoprotegerin)</measure>
    <time_frame>0-6-12 months</time_frame>
    <description>Calculate the difference in gut inflammation parameter (osteoprotegerin) among the two groups of patients at T6-T0 and T12-T6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects on gut inflammation parameter (S100-A12 protein)</measure>
    <time_frame>0-6-12 months</time_frame>
    <description>Calculate the difference in gut inflammation parameter (S100-A12 protein) among the two groups of patients at T6-T0 and T12-T6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline gut microbiota characterization</measure>
    <time_frame>baseline</time_frame>
    <description>Qualitative and quantitative (percentage) characterization of gut microbiota before the start of the therapy (T0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in gut microbiota among hypothyroid and healthy subjects</measure>
    <time_frame>baseline</time_frame>
    <description>Difference in gut microbiota among hypothyroid patients (T0) and healthy patients (data from Human Microbiome Project)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of deamidated AGA</measure>
    <time_frame>6-12-24 months</time_frame>
    <description>Estimate the incidence of positive patients to deamidated AGA at T6, T12, T24 (follow-up)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline gut inflammation parameters</measure>
    <time_frame>baseline</time_frame>
    <description>Evaluate gut inflammation (calprotectin, Osteoprotegerin and S100-A12 protein) parameters before the start of the therapy (T0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline gut absorption parameters</measure>
    <time_frame>baseline</time_frame>
    <description>Evaluate gut absorption (Steatocrit) parameters before the start of the therapy (T0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Shannon Index in the gut microbiota among liquid and solid L-Thyroxine formulations</measure>
    <time_frame>0-6-12 moths</time_frame>
    <description>Calculate the difference in Shannon Index (index of diversity) among the two groups of patients at T6-T0 and T12-T6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Chao I in gut microbiota among liquid and solid L-Thyroxine formulations</measure>
    <time_frame>0-6-12 moths</time_frame>
    <description>Calculate the difference in Chao I (Species richness estimator) among the two groups of patients at T6-T0 and T12-T6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in percentage of different species in gut microbiota among liquid and solid L-Thyroxine formulations</measure>
    <time_frame>0-6-12 moths</time_frame>
    <description>Calculate the difference in percentage of different species (OTU, operational taxonomic unit) among the two groups of patients at T6-T0 and T12-T6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Solid L-Thyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assume L-Thyroxine (tablet, per os) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).
Dosage in children with hypothyroidism:
0-6 months: 10 mcg/kg body weight/die 6-12 months: 8 mcg/kg body weight/die
1- 5 years: 6 mcg/kg body weight/die 5-10 years: 4 mcg/kg body weight/die
Dosage in adults:
initial dose of 50mcg/die; maintenance dose 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).
Dosage will be adjusted according to TSH level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquid L-Thyroxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assume L-Thyroxine (oral drops, solution) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).
Dosage in children with acquired hypothyroidism:
initial dose: 12,5-50 mcg/die maintenance dose: 100-150 mcg/m2 body surface area
Dosage in adults:
initial dose: 50 mcg/die; maintenance dose: 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).
Dosage will be adjusted according to TSH level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Thyroxine (tablet, per os)</intervention_name>
    <arm_group_label>Solid L-Thyroxine</arm_group_label>
    <other_name>Eutirox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Thyroxine (oral drops, solution)</intervention_name>
    <arm_group_label>Liquid L-Thyroxine</arm_group_label>
    <other_name>Tirosint</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with primary acquired hypothyroidism that require Levothyroxine therapy
             (naïve patients, &lt; 18 years)

          -  Informed consent from parents and patient

        Exclusion Criteria:

          -  Age &lt; 3 years

          -  Patients with secondary hypothyroidism, euthyroid sick syndrome or thyroid hormone
             resistant

          -  Patients with celiac disease, type I diabetes or other known autoimmune diseases

          -  Patients with genetic diseases or syndromes, such as Down, Williams-Beuren, Turner

          -  Assumption of antibiotics, probiotics, prebiotics, or other medications that could
             affect the gut microbiota in the month before the beginning of the study

          -  Gastrointestinal infectious diseases in the month before the beginning of the study

          -  Hypersensitivity to levothyroxine or any of the ingredients contained in the two
             pharmaceutical formulations

          -  Untreated adrenal insufficiency, untreated pituitary insufficiency and untreated
             thyrotoxicosis.

          -  Patients with cardiovascular disease

          -  Patients who show with impaired pancreatic function measured using the assay in faecal
             fat (steatocrit) at the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefano Stagi, MD</last_name>
    <phone>+0555662585</phone>
    <email>stefano.stagi@meyer.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meyer Children's Hospital</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Stagi, MD</last_name>
      <phone>+390555662585</phone>
      <email>stefano.stagi@meyer.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Stagi S, Manoni C, Cecchi C, Chiarelli F, de Martino M. Increased risk of coeliac disease in patients with congenital hypothyroidism. Horm Res Paediatr. 2011;76(3):186-92. doi: 10.1159/000328723. Epub 2011 Jul 15.</citation>
    <PMID>21757873</PMID>
  </reference>
  <reference>
    <citation>Smith DW, Klein AM, Henderson JR, Myrianthopoulos NC. Congenital hypothyroidism--signs and symptoms in the newborn period. J Pediatr. 1975 Dec;87(6 Pt 1):958-62.</citation>
    <PMID>1237554</PMID>
  </reference>
  <reference>
    <citation>Robertson HM, Narayanaswamy AK, Pereira O, Copland SA, Herriot R, McKinlay AW, Bevan JS, Abraham P. Factors contributing to high levothyroxine doses in primary hypothyroidism: an interventional audit of a large community database. Thyroid. 2014 Dec;24(12):1765-71. doi: 10.1089/thy.2013.0661.</citation>
    <PMID>25203248</PMID>
  </reference>
  <reference>
    <citation>Sánchez E, Donat E, Ribes-Koninckx C, Fernández-Murga ML, Sanz Y. Duodenal-mucosal bacteria associated with celiac disease in children. Appl Environ Microbiol. 2013 Sep;79(18):5472-9. doi: 10.1128/AEM.00869-13. Epub 2013 Jul 8.</citation>
    <PMID>23835180</PMID>
  </reference>
  <reference>
    <citation>Ianiro G, Mangiola F, Di Rienzo TA, Bibbò S, Franceschi F, Greco AV, Gasbarrini A. Levothyroxine absorption in health and disease, and new therapeutic perspectives. Eur Rev Med Pharmacol Sci. 2014;18(4):451-6. Review.</citation>
    <PMID>24610609</PMID>
  </reference>
  <reference>
    <citation>Chao T, Wang JR, Hwang B. Congenital hypothyroidism and concomitant anomalies. J Pediatr Endocrinol Metab. 1997 Mar-Apr;10(2):217-21.</citation>
    <PMID>9364356</PMID>
  </reference>
  <reference>
    <citation>Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003 Feb 8;361(9356):512-9. Review.</citation>
    <PMID>12583961</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Meyer Children's Hospital</investigator_affiliation>
    <investigator_full_name>Stefano Stagi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Hypothyroidism</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Thyroid hormone</keyword>
  <keyword>L-Thyroxine</keyword>
  <keyword>Celiac disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

